Cargando…

Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer

BACKGROUND: This study is designed to investigate the clinical value of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer. METHODS: A total of 412 lung cancer patients admitted to Cangzhou People’s Hospital from March 2018 to March 2020 were...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Feng, Song, Jian, Xu, Beizheng, Wang, Jiang, Mao, Jianjun, Liu, Haiyan, Li, Xuanmei, Deng, Aibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656695/
https://www.ncbi.nlm.nih.gov/pubmed/33176740
http://dx.doi.org/10.1186/s12885-020-07444-6
_version_ 1783608403474513920
author Xu, Feng
Song, Jian
Xu, Beizheng
Wang, Jiang
Mao, Jianjun
Liu, Haiyan
Li, Xuanmei
Deng, Aibing
author_facet Xu, Feng
Song, Jian
Xu, Beizheng
Wang, Jiang
Mao, Jianjun
Liu, Haiyan
Li, Xuanmei
Deng, Aibing
author_sort Xu, Feng
collection PubMed
description BACKGROUND: This study is designed to investigate the clinical value of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer. METHODS: A total of 412 lung cancer patients admitted to Cangzhou People’s Hospital from March 2018 to March 2020 were collected and divided into test group and control group based on their treatment schedules. The test group received systemic chemotherapy combined with bronchoscopic interventional cryotherapy, while the control group received systemic chemotherapy alone. Tumor objective response rate (ORR), disease control rate (DCR), serum tumor marker levels, serum matrix metalloproteinase (MMP) content, T cell subset level, survival time and adverse reactions of the two groups were observed. RESULTS: The ORR and DCR of the test group were better than those of the control group, while those of the non-small cell lung cancer (NSCLC) patients in the test group were better than patients with small-cell lung cancer (SCLC) (P <  0.05). There was no significant difference in serum tumor marker levels, MMP content and T cell subset level between the two groups before treatment. After treatment, the serum tumor marker levels along with serum MMP-2, MMP-9 and CD8(+) levels in the test group decreased more remarkably, while CD4(+) and CD4(+)/CD8(+) levels increased more significantly than those in the control group (P <  0.05). The serum MMP-2 and MMP-9 of NSCLC patients in the test group decreased more remarkably than those of SCLC patients, while there was no significant difference in CD8(+), CD4(+) and CD4(+)/CD8(+). The progression-free survival and overall survival of the test group were obviously longer than those of the control group. The same trend was observed in NSCLC patients compared with SCLC patients in the test group (P <  0.05). CONCLUSIONS: Systemic chemotherapy combined with bronchoscopic interventional cryotherapy for lung cancer has good clinical efficacy and safety, and can be widely used in clinical practice.
format Online
Article
Text
id pubmed-7656695
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76566952020-11-12 Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer Xu, Feng Song, Jian Xu, Beizheng Wang, Jiang Mao, Jianjun Liu, Haiyan Li, Xuanmei Deng, Aibing BMC Cancer Research Article BACKGROUND: This study is designed to investigate the clinical value of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer. METHODS: A total of 412 lung cancer patients admitted to Cangzhou People’s Hospital from March 2018 to March 2020 were collected and divided into test group and control group based on their treatment schedules. The test group received systemic chemotherapy combined with bronchoscopic interventional cryotherapy, while the control group received systemic chemotherapy alone. Tumor objective response rate (ORR), disease control rate (DCR), serum tumor marker levels, serum matrix metalloproteinase (MMP) content, T cell subset level, survival time and adverse reactions of the two groups were observed. RESULTS: The ORR and DCR of the test group were better than those of the control group, while those of the non-small cell lung cancer (NSCLC) patients in the test group were better than patients with small-cell lung cancer (SCLC) (P <  0.05). There was no significant difference in serum tumor marker levels, MMP content and T cell subset level between the two groups before treatment. After treatment, the serum tumor marker levels along with serum MMP-2, MMP-9 and CD8(+) levels in the test group decreased more remarkably, while CD4(+) and CD4(+)/CD8(+) levels increased more significantly than those in the control group (P <  0.05). The serum MMP-2 and MMP-9 of NSCLC patients in the test group decreased more remarkably than those of SCLC patients, while there was no significant difference in CD8(+), CD4(+) and CD4(+)/CD8(+). The progression-free survival and overall survival of the test group were obviously longer than those of the control group. The same trend was observed in NSCLC patients compared with SCLC patients in the test group (P <  0.05). CONCLUSIONS: Systemic chemotherapy combined with bronchoscopic interventional cryotherapy for lung cancer has good clinical efficacy and safety, and can be widely used in clinical practice. BioMed Central 2020-11-11 /pmc/articles/PMC7656695/ /pubmed/33176740 http://dx.doi.org/10.1186/s12885-020-07444-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Xu, Feng
Song, Jian
Xu, Beizheng
Wang, Jiang
Mao, Jianjun
Liu, Haiyan
Li, Xuanmei
Deng, Aibing
Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
title Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
title_full Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
title_fullStr Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
title_full_unstemmed Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
title_short Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
title_sort clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656695/
https://www.ncbi.nlm.nih.gov/pubmed/33176740
http://dx.doi.org/10.1186/s12885-020-07444-6
work_keys_str_mv AT xufeng clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer
AT songjian clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer
AT xubeizheng clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer
AT wangjiang clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer
AT maojianjun clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer
AT liuhaiyan clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer
AT lixuanmei clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer
AT dengaibing clinicalstudyofsystemicchemotherapycombinedwithbronchoscopicinterventionalcryotherapyinthetreatmentoflungcancer